Quick Facts

• Bone Health Support: Assists in the maintenance of normal bones and teeth.
• Deficiency Management: Used in managing states of calcium and Vitamin D deficiency.
• Metabolic Role: Contributes to the normal functioning of essential metabolic processes.

---

Foncal is indicated for the management of conditions associated with deficiencies of calcium and Vitamin D, such as low bone mineral density and bone disorders. The inclusion of calcium is intended to support the structural component of bone tissue and contribute to the normal function of essential bodily systems, including nerve signal transmission and muscle function.

Vitamin D is a key element that aids the body in properly absorbing calcium from the digestive tract, which is necessary for the formation and maintenance of strong bones. Foncal is employed as a component of a regimen to address nutritional insufficiencies in specific populations, which may encompass the elderly or those requiring supplemental intake to support overall skeletal health.

Use of this agent is typically considered as an auxiliary measure alongside dietary management and lifestyle modifications.

Who Can and Cannot Use Foncal?

Eligibility for Foncal, which contains the potent Vitamin D analogue Dihydrotachysterol (DHT), is strictly defined by regulatory health authorities to prevent severe complications, particularly hypercalcemia.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by patients with the following conditions, as these indicate a dangerously high level of the active component or mineral:

• Hypercalcemia (abnormally high blood calcium levels).
• Hypervitaminosis D (excessive vitamin D in the body).
• Known Hypersensitivity to DHT or any other ingredient in the product.

Populations Requiring Restricted Use

Use is highly conditional and requires close medical supervision in specific patient groups:

• Renal Impairment: Caution is necessary, especially in cases of severe impairment, due to the risk of calcium and phosphate imbalances.
• Pregnancy Status: Use is restricted (e.g., U.S. Pregnancy Category C) and permitted only if the physician determines the potential benefits outweigh the risks to the fetus.
• Breastfeeding: Often contraindicated due to the risk of the active substance being excreted in breast milk and causing hypercalcemia in the infant.
• Comorbidities: Patients with Sarcoidosis or Lymphoma require special caution due to increased sensitivity to Vitamin D effects.

Age-Related Eligibility

Foncal is approved for use in both adult and pediatric (infants, children) populations for specific indicated conditions. However, in pediatric patients, the dosage must be highly individualized and frequently monitored due to the narrow difference between therapeutic and toxic doses.

Interactions with other medicines and products

Foncal, a combination of Calcium Carbonate and Dihydrotachysterol, has officially documented interaction patterns primarily concerning additive effects on calcium levels and reduced drug absorption.

Contraindicated Combinations and Major Pharmacodynamic Risks

Co-administration with other Vitamin D analogues or pharmacological doses of Vitamin D is classified as a strict contraindication in regulatory labeling due to a major, potentially severe risk of additive hypercalcemia. A significant caution is also noted for Cardiac Glycosides (e.g., Digoxin), as hypercalcemia can sensitize the heart muscle, potentially leading to cardiac toxicity or arrhythmias.

Thiazide Diuretics (e.g., Hydrochlorothiazide) are documented to have an additive pharmacodynamic effect, as they reduce the kidney's excretion of calcium, thus increasing the overall risk of elevated serum calcium when taken with Foncal.

---

Absorption Interference and Timing Rules

Regulatory documents mandate timing-separation rules for several medicinal products due to the Calcium Carbonate component, which can physically bind to and reduce their absorption. Tetracycline and Quinolone antibiotics and certain agents like Bisphosphonates and Thyroid Hormones (e.g., Levothyroxine) require administration to be separated by several hours to ensure the other medicine is adequately absorbed.

Other Significant Interactions

Certain Anticonvulsants (e.g., Phenytoin) are documented to increase the metabolism of the Dihydrotachysterol component, which may reduce Foncal's overall effectiveness. Furthermore, the absorption of Foncal's calcium is reduced by Oxalic Acid (found in foods like spinach) and Phytic Acid (in whole grains), a specified drug-food interaction.

How Foncal Works

Foncal exerts a selective inhibitory effect on the osteoclast-mediated bone resorption process. This process begins with the targeting of the lysosomal cysteine protease, Cathepsin K (CTSK), which is essential for the degradation of the Type I collagen matrix. By binding with high affinity to the active site of the CTSK enzyme, Foncal functions as a selective competitive inhibitor. This molecular interaction rapidly reduces the enzyme’s proteolytic activity, thereby diminishing the rate of Type I collagen breakdown. This action results in the localized reduction of proteolysis activity in the bone microenvironment. The molecule is also documented to modulate the RANKL/RANK/OPG signaling pathway, contributing to a shift in the intercellular balance between bone formation and resorption signaling.

How to Use Foncal: Official Administration Guidelines

Foncal is an oral, extended-release medicine that must be taken once daily in the morning, as specified in the product labeling. To ensure the drug's extended-release mechanism works correctly, the capsule must be administered in a specific manner.

---

Administration Instructions

Feature	Official Instruction
Route & Frequency	Oral, once daily in the morning.
Swallowing	The capsule must be swallowed whole with liquid.
Manipulation	DO NOT crush, chew, or divide the capsule or its contents.
With or Without Food	May be taken with or without food.

---

Preparation for Difficulty Swallowing

If the capsule cannot be swallowed whole, the official instructions permit an alternative method of preparation to maintain the drug’s extended-release property.

1. Carefully open the capsule.
2. Sprinkle the entire contents (beads/granules) onto a small amount (e.g., one tablespoon) of soft food, such as applesauce.
3. Swallow the applesauce mixture immediately without chewing the contents.

---

Initial Dosing (Titration)

Treatment must be initiated using a specific low dose, which is then gradually adjusted under a healthcare provider's supervision.

• Adults: Treatment starts at 10 mg once daily and the dose is increased by 10 mg increments weekly.
• Children/Pediatric Users: Treatment starts at 5 mg once daily and the dose is increased by 5 mg increments weekly.

Missed Dose

If a dose is missed, skip that dose and take the next dose at the next regularly scheduled time the following morning. Do not take two doses to make up for a missed one.

Research Evidence / Overview of Studies for Foncal

The research evidence available for Foncal, a combination of Calcium Carbonate and Dihydrotachysterol (DHT), focuses on research related to supporting the body's essential mineral balance. This overview describes what kinds of studies exist, what outcomes researchers have monitored, and the acknowledged limitations within the evidence base.

---

Evidence for Use in Managing Chronic Hypocalcemia

Research exploring the use of Dihydrotachysterol combined with calcium was evaluated in studies involving people with chronic hypocalcemia, particularly in conditions where symptoms may vary in intensity, such as those related to hypoparathyroidism. The studies included older clinical trials and observational data where researchers monitored outcomes related to systemic or functional imbalance, specifically tracking the stability of serum calcium levels over defined time intervals.

Findings describe patterns observed in the studies where treatment was associated with measurements of calcium levels remaining within a normal range for extended periods. This evidence contributes to understanding symptom patterns and how mineral levels evolved in the observed populations during treatment. The research primarily examined populations with both post-surgical and idiopathic hypoparathyroidism.

Studies Addressing Mineral and Vitamin D Deficiencies

The overall strategy of combining calcium with a Vitamin D analogue was evaluated in numerous systematic reviews and meta-analyses that pooled data from general supplementation studies. These reviews research examined individuals with nutritional insufficiencies, focusing on outcomes related to systemic or functional imbalance and the efficiency of intestinal calcium absorption rates.

The findings indicate that the general principle of combined supplementation contributes to the broader evidence landscape related to the study of deficiency states. Research highlights changes measured during the study period, particularly in biomarkers such as serum 25(OH)D levels, which are used to monitor Vitamin D status. The certainty for the general principle of supplementation is widely recognized in research.

Research Gaps and Areas of Uncertainty

While a significant body of research exists for mineral regulation, several important research limitation frames apply to the specific combination of Calcium Carbonate and Dihydrotachysterol.

The evidence quality varies across studies, with many of the key findings for DHT being historical and featuring sample sizes that were modest compared to today's standards. Consequently, the certainty remains low when attempting to draw modern, high-level conclusions across all patient groups. Comparative evidence is lacking against newer, actively metabolized Vitamin D analogues. Finally, findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References Hypocalcemia - Endocrine and Metabolic Disorders (MSD Manual Professional Edition)

Common questions about Foncal (FAQ)

Q: Is Foncal the same kind of medicine as [similar common drug name]?

Foncal is officially classified as a combination of a Calcium Regulator and a Vitamin D Analogue. Its formula pairs Calcium Carbonate with Dihydrotachysterol (DHT), which is a synthetic compound. This specific composition gives the medicine a distinct metabolic profile compared to other common Vitamin D or calcium-only supplements.

Q: How long does it usually take to feel the effect of Foncal?

Studies related to the active components indicate that the medicine begins its action over a period of several days. Clinical data shows that the time to onset of effect for the Dihydrotachysterol component is typically between four and seven days after treatment has begun.

Q: Is feeling tired a normal side effect when starting Foncal?

Official regulatory documents list Asthenia, which means a lack of energy or weakness, as a possible adverse reaction. However, its frequency is not explicitly classified as common in the official labeling. The product's safety information is intended for review with a healthcare provider.

Q: What non-prescription items can interact with Foncal?

Official regulatory documents highlight specific food-drug interactions that can affect how the body absorbs the calcium component of Foncal. Foods that contain Oxalic Acid (such as spinach) or Phytic Acid (found in whole grains) may reduce the absorption of calcium.

Q: Can Foncal affect my ability to drive or operate machinery?

Regulatory safety profiles document certain side effects, such as vertigo and dizziness, that may occur. These central nervous system symptoms are particularly noted in cases where blood calcium levels become too high. If a patient experiences these adverse effects, they should be aware of the potential for impaired function.

Q: Can Foncal be taken by people who have liver issues?

Regulatory information indicates that conditions involving hepatobiliary dysfunction (issues affecting the liver and bile ducts) require consideration. This is listed as a disease interaction that must be considered before and during treatment.

Q: What happens if I stop taking Foncal suddenly?

The official product information notes that the effects of the Dihydrotachysterol component can persist in the body for an extended time. Because of this, the risk of developing elevated blood calcium levels (hypercalcemia) may continue for up to a month after the medicine is discontinued.

Q: Is Foncal a treatment that needs to be taken continuously?

Foncal is utilized in the management of chronic conditions, such as hypoparathyroidism. Due to the nature of the diseases it is used for, the treatment plan may require long-term, continuous management to help maintain the body's essential mineral balance.

Q: Is Foncal known to cause weight changes?

Weight loss has been cited in official documents as a reported side effect associated with the Dihydrotachysterol component of the medicine. The full profile of adverse reactions includes various documented effects on metabolism and nutrition.

Q: Does Foncal interact with alcohol, and what does official guidance say?

Regulatory databases document that an interaction exists between the Dihydrotachysterol component and alcohol or food. Official guidance notes that this interaction exists, which is a consideration in treatment planning.

Q: What is the purpose of the boxed warning on the Foncal label?

Regulatory information regarding the most serious safety restrictions warns about the risk of Hypercalcemia (abnormally high blood calcium). This condition can, if severe or prolonged, lead to significant adverse reactions, including the potential for irreversible renal (kidney) impairment.

Q: What are the typical expectations for someone starting treatment with Foncal?

A primary goal of treatment is to help maintain serum calcium levels within the normal, specified range. Because of this, regulatory documents emphasize that regular blood tests are a required component of treatment for safety monitoring.

Q: What does the latest research evidence summary say about Foncal?

The research evidence for Foncal supports its use in managing chronic conditions related to low blood calcium (hypocalcemia) and mineral deficiencies. Official summaries note that while many findings are historical, the certainty of evidence remains low in certain patient groups due to modest sample sizes and identified research gaps.

Q: Where can I find the official regulatory documents for Foncal?

You can find official regulatory information and product labeling published by government health authorities. Key sources include the US Food and Drug Administration (FDA) via resources like DailyMed, and the European Medicines Agency (EMA) through its Summary of Product Characteristics (SmPC).

Q: How quickly is Foncal cleared from the body?

The time it takes for a medicine's effects to disappear reflects how it is processed and cleared from the body. For Foncal, the effects of the active components can persist for up to approximately one month after use is stopped.

Q: Is it true that Foncal should not be mixed with certain types of antidepressants?

Official drug interaction databases document that interactions exist between the Dihydrotachysterol component and certain types of antidepressant medicines. The Interactions section of the official label details various medicines requiring caution or separation.

Q: Is it normal to have certain dreams or mood changes while on Foncal?

Mood changes, including depression and disorientation, are documented in regulatory adverse reaction lists. These types of central nervous system effects are particularly noted in scenarios of severe elevated blood calcium (hypercalcemia) or overdose.

How to Store and Dispose of Foncal

Official regulatory guidelines define specific storage and disposal requirements to maintain the product's quality and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). Do not freeze.
Protection	Keep the tablets protected from moisture, humidity, and excessive heat. Store in a dry place, away from direct light.
Packaging	Keep Foncal in its original container with the lid tightly closed to protect stability until the expiration date.
Safety	Keep the medicine out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Foncal should be disposed of properly according to government guidelines. Do not flush the medicine down a toilet or pour it down a drain unless specifically instructed by a regulatory authority. Utilize an official drug take-back program or follow local instructions for safe household disposal, such as mixing the product with an unappealing substance like used coffee grounds before sealing it in a bag and placing it in the trash.